Your browser is no longer supported. Please, upgrade your browser.
Settings
EYPT EyePoint Pharmaceuticals, Inc. daily Stock Chart
EYPT [NASD]
EyePoint Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.47 Insider Own0.60% Shs Outstand115.53M Perf Week-8.75%
Market Cap89.01M Forward P/E5.81 EPS next Y0.12 Insider Trans17.04% Shs Float76.58M Perf Month-11.41%
Income-50.70M PEG- EPS next Q-0.11 Inst Own54.30% Short Float5.88% Perf Quarter-5.28%
Sales25.80M P/S3.45 EPS this Y-3.60% Inst Trans7.85% Short Ratio5.12 Perf Half Y-51.02%
Book/sh0.14 P/B5.14 EPS next Y136.40% ROA-62.70% Target Price- Perf Year-55.83%
Cash/sh0.21 P/C3.38 EPS next 5Y- ROE-294.30% 52W Range0.70 - 2.69 Perf YTD-53.55%
Dividend- P/FCF- EPS past 5Y-35.80% ROI- 52W High-72.86% Beta1.34
Dividend %- Quick Ratio4.50 Sales past 5Y-5.20% Gross Margin87.10% 52W Low4.30% ATR0.07
Employees84 Current Ratio4.80 Sales Q/Q275.00% Oper. Margin- RSI (14)39.17 Volatility7.03% 10.40%
OptionableYes Debt/Eq2.90 EPS Q/Q43.40% Profit Margin- Rel Volume0.34 Prev Close0.72
ShortableYes LT Debt/Eq2.90 EarningsMay 06 BMO Payout- Avg Volume878.56K Price0.73
Recom2.20 SMA20-11.18% SMA50-14.38% SMA200-47.39% Volume125,696 Change1.40%
Apr-06-20Downgrade B. Riley FBR Buy → Neutral $4 → $1
Nov-04-19Resumed Laidlaw Buy $5
Sep-12-19Initiated Guggenheim Buy
Jul-02-20 07:59AM  
Jun-24-20 01:01PM  
Jun-18-20 08:42AM  
May-27-20 12:50PM  
May-26-20 07:00AM  
May-18-20 07:00AM  
May-06-20 08:45AM  
08:21AM  
07:00AM  
Apr-29-20 08:00AM  
Apr-08-20 06:10AM  
Apr-01-20 11:35AM  
Mar-31-20 10:54AM  
Mar-23-20 11:39PM  
Mar-05-20 08:25AM  
07:00AM  
Mar-02-20 07:00AM  
Feb-27-20 07:00AM  
Feb-21-20 09:09AM  
07:46AM  
Feb-20-20 04:01PM  
Feb-18-20 07:00AM  
Feb-04-20 07:51AM  
Feb-03-20 05:24PM  
Jan-30-20 07:56AM  
Jan-27-20 07:00AM  
Jan-23-20 07:00AM  
Dec-22-19 05:31PM  
Dec-04-19 07:00AM  
Nov-25-19 06:46PM  
Nov-19-19 10:54AM  
Nov-14-19 07:00AM  
Nov-07-19 07:30AM  
06:00AM  
Nov-04-19 07:00AM  
Nov-01-19 07:00AM  
Oct-31-19 10:35AM  
Oct-24-19 07:00AM  
Oct-02-19 04:05PM  
Sep-27-19 07:00AM  
Sep-26-19 07:00AM  
Sep-09-19 07:00AM  
Sep-06-19 08:32AM  
Aug-23-19 11:24AM  
Aug-07-19 07:35AM  
06:00AM  
Jul-31-19 10:36AM  
07:06AM  
Jul-30-19 04:15PM  
Jul-25-19 07:00AM  
Jul-24-19 07:00AM  
Jul-23-19 07:00AM  
Jul-15-19 07:00AM  
Jul-08-19 09:13AM  
Jul-01-19 07:00AM  
Jun-29-19 05:26PM  
Jun-13-19 07:00AM  
Jun-10-19 07:00AM  
May-17-19 04:39AM  
May-15-19 07:00AM  
May-08-19 07:30AM  
06:13AM  
06:00AM  
May-01-19 10:32AM  
07:00AM  
Apr-23-19 07:00AM  
Apr-16-19 07:00AM  
Apr-02-19 07:00AM  
Mar-28-19 12:44PM  
09:11AM  
Mar-27-19 04:05PM  
Mar-20-19 12:18PM  
Mar-14-19 04:35PM  
09:30AM  
08:25AM  
06:00AM  
Mar-13-19 07:27AM  
Mar-12-19 04:15PM  
Feb-14-19 07:00AM  
Feb-13-19 04:15PM  
Feb-04-19 07:00AM  
Jan-30-19 10:31AM  
Jan-28-19 07:00AM  
Jan-03-19 10:35AM  
07:00AM  
Dec-17-18 04:23PM  
Nov-29-18 08:46AM  
Nov-27-18 04:05PM  
Nov-12-18 07:00AM  
Nov-06-18 04:10PM  
07:30AM  
07:04AM  
06:22AM  
06:00AM  
Nov-05-18 04:11PM  
Oct-30-18 07:30AM  
07:00AM  
Oct-29-18 07:00AM  
Oct-18-18 07:00AM  
Oct-17-18 11:42AM  
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. The company also offers DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. In addition, it develops YUTIQ shorter-acting uveitis for the treatment of NIPU; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Further, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, and Ocumension Therapeutics. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jones David ScottSVP & Chief Commercial OfficerJun 30Option Exercise0.0041,050041,050Jul 02 06:15 PM
Paggiarino Dario A.Chief Medical OfficerJun 30Option Exercise0.0041,0500101,193Jul 02 06:14 PM
Lurker NancyPresident & CEOJun 30Option Exercise0.00124,6670784,467Jul 02 06:13 PM
Lurker NancyPresident & CEOJun 27Option Exercise0.0040,0000659,800Jun 30 07:40 PM
Paggiarino Dario A.Chief Medical OfficerJun 27Option Exercise0.0010,000063,079Jun 30 07:52 PM
Lurker NancyPresident & CEOJun 14Option Exercise0.0045,0000619,800Jun 16 05:03 PM
Paggiarino Dario A.Chief Medical OfficerJun 14Option Exercise0.0014,200057,247Jun 16 05:00 PM
Elston GeorgeChief Financial OfficerMar 12Buy0.9610,0009,60020,000Mar 13 08:41 AM
Lurker NancyPresident & CEOMar 10Buy1.0698,000104,027574,800Mar 11 08:40 AM
Lurker NancyPresident & CEOFeb 21Option Exercise0.00137,1740476,800Feb 25 04:50 PM
Elston GeorgeChief Financial OfficerNov 15Buy1.4310,00014,29010,000Nov 18 08:42 AM